Clevexel

Board of Directors

A senior advisory board formed by renowned experts and managers with international experience in a large spectrum of complementary fields

Marc LE BOZEC CVXL

Chief Executive Officer of Clevexel Pharma, Marc is also Fund manager at Arbevel, CEO of CYTOO (France) and CEO of MDoloris. From 2006 until 2013 Marc was the CFO of Cellectis, where he raised ca. €120m on capital markets. Prior to this he started his own Business BioProtein Technologies and headed it after several years of organizational consulting at Bossard Consultants and strategy consulting at Arthur D. Little. Marc is graduated from HEC School of Management.

Christian has more than 30 years of experience in R&D, Manufacturing and Regulatory affairs. Before founding Clevexel Pharma, Christian was site manager and senior director of drug development for Europe at Cephalon Inc.. Prior to Cephalon, he was Senior Director of R&D in Immune Mediated Diseases and Transplant at Genzyme. He was previously on the Board of Directors of Cassenne Laboratory (Hoechst Marion Roussel group), Flamel Technology, and Genzyme Polyclonals. Christian is the author of more than 35 peer-reviewed articles and 6 patents, including one on the Central Nervous System. He holds a Ph.D. in Immuno-hematology from the Paris VI University.

Gilles2

A Board member or adviser for several Pharma and Biotech companies (GABC – Gilles Avenard Biotech Consulting) and Chief Executive Officer of G1J-IDF, a seed venture fund in Life Sciences, from 1997 to 2010 Gilles served as Chief Operating Officer of BioAlliance Pharma SA (BIO – NYSE-EURONEXT), a company he co-founded. From 1990 to 1997, He served as Medical Director of Development in the Cassenne Laboratories division of Hoechst Marion Roussel (Sanofi-Aventis Pharma). From 1976 to 1990, he held various positions with the National Blood Transfusion Center in Paris, including Medical Director of Bio-Transfusion (LFB), providing human plasma products.

Antoine has started his career in M&A before joining Ernst & Young (Transaction Advisory Services). Antoine became later CFO of a luxury company. He graduated from ESCP-EAP.

Stanislas is Doctor of Pharmacy and is a graduate from the ESSEC Business School. He joined CleveXel Pharma in April 2013 to develop and structure the financial department and to assist the CEO in fund raising and business development. After his MBA, Stanislas began his career in the pharmaceutical industry as product manager junior at Johnson & Johnson (Paris office). He worked as Junior Associate in a French Venture Capital fund specialized in Biotechnology. He spent two years as senior consultant in the Corporate Restructuring & Transaction Services department of Ernst & Young and three years as Senior Associate at Duff & Phelps Paris working primarily with the Merger and Acquisition team. In 2011, Stanislas joined Rarecells Diagnostics to be in charge of corporate affairs and assist the founder in fund raising and business development.